Accessibility Menu
Nautilus Biotechnology logo

Nautilus Biotechnology(NASDAQ) NAUT

Market Cap$152.49MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-89%
5 Year-85%
1 Year+53%
1 Month-40%
$1.09
-9.58%
-0.11Today
Nautilus Biotechnology last closing stock price
MetricPriceDate
Last closeUSD 1.202026-07-28
Nautilus Biotechnology stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-29.41%USD 1.702026-07-21
1 month-40%USD 2.002026-06-26
3 month-52%USD 2.502026-04-29
Year to date-38.46%USD 1.952025-12-31
1 year+53.37%USD 0.782025-07-28
3 year-60.91%USD 3.072023-07-28
5 year-84.98%USD 7.992021-07-29
Since inception-88.51%USD 10.442020-08-07

Nautilus Biotechnology Financials at a Glance

Market Cap

$152.49MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$190.00K

Net Income (TTM)

-$56.52M

EPS (TTM)

-$0.45

P/E Ratio

-2.66

Dividend

$0.00

Beta (Volatility)

1.63 (High)

Price

$1.09

Volume

1,089,141.207

Open

$1.21

Previous Close

$1.20

Daily Range

$1.07 - $1.23

52-Week Range

$0.62 - $4.31

Estimated Earnings Date

Nov 3, 2026

NAUT News

No articles available.

NAUT: Motley Fool Moneyball Superscore

57

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nautilus Biotechnology

Nautilus makes tools to study proteins in the body. It helps scientists find better ways to treat illnesses. The system measures billions of single protein molecules quickly.

Decoding the Body's Proteins

  • Voyager Platform: A complete system used to study proteomics, which is the large-scale study of proteins in the body.
  • Tau Assay: A specialized biological test designed to analyze protein versions linked to Alzheimer's disease.
  • Consumables: Chemical testing supplies and biological markers required to perform analysis on the hardware.

Moving Toward Market Launch

  • Joined with ARYA Sciences Acquisition Corp III in June 2021 to become a publicly traded company.
  • Launched an Early Access Program in January 2026 to provide protein testing services to research partners.
  • Formed a stock sale agreement with Cowen and Company, LLC in February 2024 to support future funding needs.
  • Hired the first sales employee in early 2026 to start building a commercial distribution network.

A New Way to Measure

Nautilus uses a method called Iterative Mapping to identify billions of individual protein molecules with high precision. This technique creates a digital map of the protein landscape to help researchers understand human health.

Tracking the Numbers

  • Net loss hit $14.7 million in Q1 2026, an 11.5% improvement from Q1 2025.
  • Total operating expenses reached $16.1 million in Q1 2026, down 14.4% year-over-year.
  • Free cash flow reached negative $13.6 million in Q1 2026, which narrowed by 3.9% from the previous year.
  • Total cash and short-term investments hit $95.9 million on March 31, 2026.

The Final Word

Nautilus is moving from a development phase toward selling its first commercial protein analysis tools. The company aims to advance human medicine by providing deeper data on the proteins that drive disease.

AI Generated • May 12, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

130

CEO

Sujal M. Patel

Website

www.nautilus.bio

Headquarters

Seattle, WA 98102, US

NAUT Financials

Key Financial Metrics (TTM)

Gross Margin

-1595.79%

Operating Margin

-33043.68%

Net Income Margin

-29747.89%

Return on Equity

-37.58%

Return on Capital

-35.74%

Return on Assets

-34.55%

Earnings Yield

-37.59%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$152.49MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

127.08M

Volume

1.09M

Avg. Volume

716.72K

Financials (TTM)

Gross Profit

-$3.03M

Operating Income

-$62.78M

EBITDA

-$53.13M

Operating Cash Flow

-$50.24M

Capital Expenditure

-$1.63M

Free Cash Flow

-$51.86M

Cash & ST Invst.

$84.03M

Total Debt

$27.82M

Nautilus Biotechnology Performance Analysis

Nautilus Biotechnology annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Nautilus Biotechnology sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Nautilus Biotechnology annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.46-22.0%
20232023-12-31USD -0.519.6%
20242024-12-31USD -0.5610.7%
20252025-12-31USD -0.47-17.2%
Nautilus Biotechnology sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-308.3%
Q42025-12-31N/A
Q12026-03-31-9.1%
Q22026-06-308.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$190.00K

N/A

Gross Profit

$1.65M

+201.1%

Gross Margin

8.69%

N/A

Market Cap

$152.49MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.20M

N/A

Employees

127

N/A

Net Income

-$14.47M

+3.8%

EBITDA

-$15.76M

-17.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$84.03M

-43.2%

Total Debt

$27.82M

-1.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$23.83M

-0.6%

Short Term Debt

$3.99M

-5.5%

Return on Assets

-34.55%

N/A

Return on Invested Capital

-40.52%

N/A

Free Cash Flow

-$14.18M

-3.2%

Operating Cash Flow

-$13.73M

-2.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IMRXImmuneering Corporation
$4.13-2.50%
TNYATenaya Therapeutics, Inc.
$0.75-0.95%
ARCTArcturus Therapeutics Holdings Inc.
$5.79+0.70%
PYXSPyxis Oncology, Inc.
$3.05+4.81%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOFISoFi Technologies
$15.68-0.06%
INTCIntel
$86.30+0.00%
NVDANvidia
$195.72-0.01%
FFord Motor Company
$15.72+0.05%

Questions About NAUT

What is the current price of Nautilus Biotechnology?

Nautilus Biotechnology is trading at $1.08 per share.

What is the 52-week range for Nautilus Biotechnology?

Over the past 52 weeks, Nautilus Biotechnology has traded between $0.62 and $4.31.

How much debt does Nautilus Biotechnology have?

As of the most recent reporting period, Nautilus Biotechnology reported total debt of $27.82M.

How much cash does Nautilus Biotechnology have on hand?

Nautilus Biotechnology reported $13.17M in cash and cash equivalents in its most recent financial results.

What is Nautilus Biotechnology’s dividend yield?

Nautilus Biotechnology does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services